Business Segments Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-20 EDT
|
5-day change | 1st Jan Change | ||
| 55.25 USD | -2.23% |
|
+4.13% | +25.43% |
| 08-10 | Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date | MT |
| 08-10 | Novo Nordisk works to address FDA's findings at Indiana plant | FW |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Pharmaceuticals | 18.82M | 33.19M | - | - | - | |||||
Total Assets | 304M | 358M | 311M | 475M | 404M | |||||
Interest Expense | - | - | -6.5M | -6.84M | -6.89M | |||||
CAPEX | -5.25M | -1.06M | -71K | -98K | -602K | |||||
EBT | -132M | -135M | -166M | -246M | -378M | |||||
D&A | 2.63M | 2.99M | 2.84M | 1.94M | 1.66M | |||||
Operating Income | -130M | -134M | -171M | -252M | -385M | |||||
Net Income | -132M | -135M | -166M | -246M | -378M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 18.82M | 33.19M | - | - | - | |||||
Total Assets | 304M | 358M | 311M | 475M | 404M | |||||
Interest Expense | - | - | -6.5M | -6.84M | -6.89M | |||||
D&A | 2.63M | 2.99M | 2.84M | 1.94M | 1.66M | |||||
CAPEX | -5.25M | -1.06M | -71K | -98K | -602K | |||||
Net Income | -132M | -135M | -166M | -246M | -378M | |||||
EBT | -132M | -135M | -166M | -246M | -378M | |||||
Operating Income | -130M | -134M | -171M | -252M | -385M |
- Stock Market
- Stocks
- SRRK Stock
- Financials Scholar Rock Holding Corporation
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
